• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by CAI International, Inc. (Amendment)

    4/30/21 9:14:28 AM ET
    $CAI
    Medical Specialities
    Health Care
    Get the next $CAI alert in real time by email
    SC 13D/A 1 d181925dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13D/A

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENT FILED PURSUANT

    TO RULE 13d-1(a) AND AMENDMENTS THERETO

    FILED PURSUANT TO RULE 13d-2(a)

    (AMENDMENT NO. 4)1

     

     

    CAI International, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    12477X106

    (CUSIP Number)

    Weiss Asset Management LP

    c/o Georgiy Nikitin

    222 Berkeley St., 16th Floor

    Boston, MA 02116

    (617) 778-7725

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    April 29, 2021**

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13(d)-1(g), check the following box.  ☐

     

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

    (Continued on following pages)

    (Page 1 of 7 Pages)

      **

    Please see Item 5.

     

    1

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.  12477X106   13D/A   Page 2 of 7 Pages

     

      1   

    NAMES OF REPORTING PERSONS.

     

    Weiss Asset Management LP

    BIP GP LLC

    WAM GP LLC

    Andrew M. Weiss Ph.D.

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    SOURCE OF FUNDS

     

    WC

      5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Weiss Asset Management LP is a Delaware limited partnership.

    BIP GP LLC is a Delaware limited liability company.

    WAM GP LLC is a Delaware limited liability company.

    Andrew M. Weiss is a United States citizen.

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    PERSON

    WITH

     

         7    

    SOLE VOTING POWER

     

    Weiss Asset Management LP — 0 shares

    BIP GP LLC — 0 shares

    WAM GP LLC — 0 shares

    Andrew M. Weiss — 0 shares

         8   

    SHARED VOTING POWER

     

    Weiss Asset Management LP — 1,056,561 **

    BIP GP LLC — 688,045 **

    WAM GP LLC — 1,056,561 **

    Andrew M. Weiss — 1,056,561 **

         9   

    SOLE DISPOSITIVE POWER

     

    Weiss Asset Management LP — 0 shares

    BIP GP LLC — 0 shares

    WAM GP LLC — 0 shares

    Andrew M. Weiss — 0 shares

       10   

    SHARED DISPOSITIVE POWER

     

    Weiss Asset Management LP — 1,056,561 **

    BIP GP LLC — 688,045**

    WAM GP LLC — 1,056,561 **

    Andrew M. Weiss — 1,056,561 **

     

    **

    Please see Item 5.


    CUSIP No.  12477X106   13D/A   Page 3 of 7 Pages

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    Weiss Asset Management LP — 1,056,561 **

    BIP GP LLC — 688,045**

    WAM GP LLC — 1,056,561 **

    Andrew M. Weiss — 1,056,561 **

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    Weiss Asset Management LP — 6.11% **

    BIP GP LLC — 3.98% **

    WAM GP LLC — 6.11% **

    Andrew M. Weiss — 6.11% **

    14  

    TYPE OF REPORTING PERSON

     

    Weiss Asset Management LP — IA, PN

    BIP GP LLC — HC, OO

    WAM GP LLC — HC, OO

    Andrew M. Weiss — HC, IN

    This Amendment No. 4 (this “Amendment”) to Schedule 13D amends the Schedule 13D initially filed on August 23, 2019, (as amended prior to the date hereof, the “Prior Schedule 13D” and, as so amended by this Amendment, the “Schedule 13D”) with respect to the items set forth below. Capitalized terms used without definition in this Amendment have the meanings assigned to them in the Prior Schedule 13D.

    Item 3. Source and Amount of Funds or Other Consideration.

    Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    The Shares were acquired in open market purchases for an aggregate of approximately $24.74 million cash by: (i) BIP of which BIP GP LLC is the sole General Partner and (ii) Brookdale Global Opportunity Fund, a Cayman exempted company (“BGO” and together with BIP, the “Funds”), for which Weiss Asset Management LP acts as the Investment Manager.

    The source of such funds was the working capital of the Funds.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    The percentages set forth in Row 13 of the cover page and in this Item 5 have been calculated based on 17,304,111 Shares of the Issuer’s Common Stock issued and outstanding as of April 8, 2021, as reported in the Issuer’s Proxy Statement filed on April 21, 2021. Each of the Reporting Persons disclaims beneficial ownership of all of the Shares, except to the extent of its or his pecuniary interest therein, and the filing of this Schedule 13D shall not be deemed an admission of beneficial ownership of any Shares for any purpose.


    CUSIP No.  12477X106   13D/A   Page 4 of 7 Pages

     

    (a) and (b)     688,045 Shares, representing approximately 3.98% of the outstanding shares of the Issuer, are held by BIP. BIP GP LLC is the general partner of BIP. Weiss Asset Management LP is the investment manager of BIP. Dr. Weiss is the managing member of each of BIP GP LLC and WAM GP LLC and in such capacity has the power to vote and dispose of such Shares.

    368,516 Shares, representing approximately 2.13% of the outstanding shares of the Issuer, are held by BGO. Weiss Asset Management LP is the investment manager of BGO. Dr. Weiss is the managing member of WAM GP LLC and in such capacity has the power to vote and dispose of such Shares.

    See Rows 7-13 of the cover page above for the aggregate number and percentage beneficially owned by each of the Reporting Persons.

    (c)     The transactions in the Issuer’s Common Stock engaged in by BIP and BGO during the past 60 days are set forth on Schedule A hereto, which is hereby incorporated herein by reference. All of such transactions were open-market purchases.

    (d)     Other than the Funds that directly hold the securities of the Issuer, and except as set forth in this Item 5, no other person is known to have the right to receive, or the power to direct the receipt of, dividends from or proceeds from the sale, of the Shares.

    (e)     Not applicable.


    CUSIP No.  12477X106   13D/A   Page 5 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete, and correct.

    April 30, 2021

     

    WEISS ASSET MANAGEMENT LP

    BY: /S/ GEORGIY NIKITIN

    GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER
    BIP GP LLC

    BY: /S/ GEORGIY NIKITIN

    GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER
    WAM GP LLC

    BY: /S/ GEORGIY NIKITIN

    GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER

    BY: /S/ GEORGIY NIKITIN

    ATTORNEY-IN-FACT FOR ANDREW WEISS**

     

    **

    Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on January 25, 2017 in respect of its holding in Quinpario Acquisition Corp. 2.


    CUSIP No.  12477X106   13D/A   Page 6 of 7 Pages

     

    Schedule A

    Transactions Effected in Last 60 Days

    Transactions by BIP:

     

    Date

      

    Type of Transaction

      

    Number of Shares

       Purchase Price
                Per Share ($)             
     

    4/29/2021

       Open Market Sale    7964    $ 43.62  

    4/28/2021

       Open Market Sale    3132    $ 45.51  

    4/27/2021

       Open Market Sale    12243    $ 44.45  

    4/27/2021

       Open Market Sale    10419    $ 44.64  

    4/22/2021

       Open Market Sale    1197    $ 41.66  

    4/22/2021

       Open Market Sale    3256    $ 41.12  

    4/21/2021

       Open Market Sale    7878    $ 42.31  

    4/20/2021

       Open Market Sale    130    $ 43.88  

    4/19/2021

       Open Market Sale    2645    $ 44.34  

    4/16/2021

       Open Market Sale    2690    $ 44.19  

    4/15/2021

       Open Market Sale    5878    $ 45.26  

    4/14/2021

       Open Market Sale    4194    $ 46.26  

    4/13/2021

       Open Market Sale    7552    $ 44.56  

    4/12/2021

       Open Market Sale    2318    $ 45.20  

      4/9/2021

       Open Market Sale    1357    $ 43.55  

      4/8/2021

       Open Market Sale    1111    $ 43.93  

      4/7/2021

       Open Market Sale    5246    $ 45.12  

      4/6/2021

       Open Market Sale    2389    $ 45.25  

      4/5/2021

       Open Market Sale    2617    $ 47.22  

      4/5/2021

       Open Market Sale    5555    $ 46.90  

      4/1/2021

       Open Market Sale    2547    $ 45.08  

    3/31/2021

       Open Market Sale    725    $ 46.32  

    3/31/2021

       Open Market Sale    13024    $ 45.81  

    3/30/2021

       Open Market Sale    2219    $ 45.55  

    3/30/2021

       Open Market Sale    26048    $ 45.30  

    3/29/2021

       Open Market Sale    2182    $ 46.77  

    3/26/2021

       Open Market Sale    781    $ 46.85  

    Transactions by BGO:

     

    Date

      

    Type of Transaction

      

    Number of Shares

       Purchase Price
                Per Share ($)             
     

    4/29/2021

       Open Market Sale    4265    $ 43.62  

    4/28/2021

       Open Market Sale    1678    $ 45.51  

    4/27/2021

       Open Market Sale    6558    $ 44.45  

    4/27/2021

       Open Market Sale    5581    $ 44.64  

    4/22/2021

       Open Market Sale    641    $ 41.66  

     


    CUSIP No.  12477X106   13D/A   Page 7 of 7 Pages

     

    4/22/2021

       Open Market Sale    1744    $                           41.12  

    4/21/2021

       Open Market Sale    4219    $ 42.31  

    4/20/2021

       Open Market Sale    70    $ 43.88  

    4/19/2021

       Open Market Sale    1416    $ 44.34  

    4/16/2021

       Open Market Sale    1440    $ 44.19  

    4/15/2021

       Open Market Sale    3148    $ 45.26  

    4/14/2021

       Open Market Sale    2246    $ 46.26  

    4/13/2021

       Open Market Sale    4045    $ 44.56  

    4/12/2021

       Open Market Sale    1242    $ 45.20  

      4/9/2021

       Open Market Sale    731    $ 43.55  

      4/8/2021

       Open Market Sale    595    $ 43.93  

      4/7/2021

       Open Market Sale    2810    $ 45.12  

      4/6/2021

       Open Market Sale    1280    $ 45.25  

      4/5/2021

       Open Market Sale    1402    $ 47.22  

      4/5/2021

       Open Market Sale    2975    $ 46.90  

      4/1/2021

       Open Market Sale    1364    $ 45.08  

    3/31/2021

       Open Market Sale    388    $ 46.32  

    3/31/2021

       Open Market Sale    6976    $ 45.81  

    3/30/2021

       Open Market Sale    1189    $ 45.55  

    3/30/2021

       Open Market Sale    13952    $ 45.30  

    3/29/2021

       Open Market Sale    1169    $ 46.77  

    3/26/2021

       Open Market Sale    419    $ 46.85  
    Get the next $CAI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAI

    DatePrice TargetRatingAnalyst
    7/14/2025$31.00Buy
    BofA Securities
    7/14/2025$31.00Overweight
    Analyst
    7/14/2025$32.00Buy
    Guggenheim
    7/14/2025$33.00Outperform
    Evercore ISI
    7/14/2025$32.00Buy
    TD Cowen
    7/14/2025$38.00Buy
    BTIG Research
    7/14/2025$34.00Buy
    Citigroup
    7/14/2025$32.00Outperform
    Wolfe Research
    More analyst ratings

    $CAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Caris Life Sciences with a new price target

    BofA Securities initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $31.00

    7/14/25 8:49:47 AM ET
    $CAI
    Medical Specialities
    Health Care

    Analyst initiated coverage on Caris Life Sciences with a new price target

    Analyst initiated coverage of Caris Life Sciences with a rating of Overweight and set a new price target of $31.00

    7/14/25 8:49:26 AM ET
    $CAI
    Medical Specialities
    Health Care

    Guggenheim initiated coverage on Caris Life Sciences with a new price target

    Guggenheim initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $32.00

    7/14/25 8:49:05 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Poste George exercised 125,000 shares at a strike of $2.44 and covered exercise/tax liability with 139,517 shares, decreasing direct ownership by 6% to 220,237 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    8/13/25 8:07:56 PM ET
    $CAI
    Medical Specialities
    Health Care

    President Spetzler David Baxley covered exercise/tax liability with 63,509 shares, decreasing direct ownership by 12% to 460,377 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    8/13/25 8:07:06 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Halbert David D covered exercise/tax liability with 141,956 shares, decreasing direct ownership by 6% to 2,295,133 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    8/13/25 8:05:16 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®

    IRVING, Texas, Aug. 15, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Oncotarget validating the analytical and clinical performance of MI Cancer Seek®. This FDA-approved assay is used as a companion diagnostic (CDx) to identify cancer patients who may benefit from targeted therapies. It includes one pan-cancer and five tumor-specific indications for numerous FDA-approved therapies. MI Cancer Seek is the first and only test to combine whole exome sequencing (WES) and whole transcriptome sequencing (WTS) with FDA-approved CDx indications for solid tumor profiling in

    8/15/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups

    IRVING, Texas, Aug. 13, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in HER2-negative breast cancer patients. The study found that the cancer drug T-DXd worked better for patients whose tumors are hormone receptor (HR)-positive, helping them stay on treatment longer than those taking S

    8/13/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Reports Second Quarter 2025 Financial Results

    IRVING, Texas, Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported total revenue of $181.4 million, an increase of 81.3% over the corresponding prior year period.Completed 50,032 clinical therapy selection cases, an increase of 22.0% over corresponding prior year period.Reported gross margin of 62.7%, a 2,514 bps improvement over corresponding prior year period.Reported net loss

    8/12/25 4:05:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Denton John Russel returned $4,431,078 worth of shares to the company (238,230 units at $18.60), was granted 99,321 shares and bought $157,500 worth of shares (7,500 units at $21.00), decreasing direct ownership by 52% to 123,591 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/23/25 6:34:51 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Brille Brian J bought $630,000 worth of shares (30,000 units at $21.00) and was granted 132,428 shares (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/23/25 6:30:15 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Caris Life Sciences Inc.

    SCHEDULE 13G - Caris Life Sciences, Inc. (0002019410) (Subject)

    8/14/25 4:05:14 PM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Caris Life Sciences Inc.

    SCHEDULE 13G - Caris Life Sciences, Inc. (0002019410) (Subject)

    8/13/25 4:05:16 PM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Caris Life Sciences Inc.

    10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)

    8/12/25 4:59:53 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Financials

    Live finance-specific insights

    View All

    Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025

    IRVING, Texas, July 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Tuesday, August 12, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/hfsyg967 A replay of the webcast will be a

    7/23/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    CAI International, Inc. Declares Quarterly Dividend

    CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that CAI's Board of Directors declared a cash dividend of $0.30 per common share payable on September 27, 2021 to shareholders of record as of September 10, 2021. About CAI International, Inc. CAI is one of the world's leading transportation finance companies. As of June 30, 2021, CAI operated a worldwide fleet of approximately 1.9 million CEUs of containers. CAI operates through 13 offices located in 12 countries including the United States. Additional Information and Where to Find It This communication relates to the proposed merger involving the Co

    8/27/21 5:49:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    CAI International, Inc. Enters into Definitive Agreement to be Acquired by Mitsubishi HC Capital Inc.

    Purchase Price of $56.00 per Common Share in Cash CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that it has entered into a definitive agreement to be acquired by Mitsubishi HC Capital Inc. ("MHC"). Under the terms of the merger agreement with MHC (the "Merger Agreement"), MHC will acquire all of CAI's outstanding and fully diluted common stock in an all-cash transaction for $56.00 per share, which represents a total equity value of approximately $1.1 billion, consisting of $104 million (par value) of preferred stock and $986 million of common stock equity value, assuming a fully-diluted share count

    6/17/21 7:34:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by CAI International, Inc. (Amendment)

    SC 13G/A - CAI International, Inc. (0001388430) (Subject)

    12/10/21 10:00:15 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    11/12/21 9:17:56 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    10/7/21 4:07:36 PM ET
    $CAI
    Medical Specialities
    Health Care